These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 16219725)
41. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Houle JM; Strong HA Retina; 2002 Dec; 22(6):691-7. PubMed ID: 12476093 [TBL] [Abstract][Full Text] [Related]
42. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Singh CN; Saperstein DA Retina; 2008 Jun; 28(6):789-93. PubMed ID: 18536593 [TBL] [Abstract][Full Text] [Related]
43. Choroidal infarction following photodynamic therapy with verteporfin. Klais CM; Ober MD; Freund KB; Ginsburg LH; Luckie A; Mauget-Faÿsse M; Coscas G; Gross NE; Yannuzzi LA Arch Ophthalmol; 2005 Aug; 123(8):1149-53. PubMed ID: 16087856 [No Abstract] [Full Text] [Related]
44. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Lam DS; Chan WM; Liu DT; Fan DS; Lai WW; Chong KK Br J Ophthalmol; 2004 Oct; 88(10):1315-9. PubMed ID: 15377558 [TBL] [Abstract][Full Text] [Related]
45. Hot spots after photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Battaglia Parodi M; Da Pozzo S Retina; 2002 Oct; 22(5):671-3. PubMed ID: 12441743 [No Abstract] [Full Text] [Related]
46. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Abrams P Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187 [TBL] [Abstract][Full Text] [Related]
47. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Axer-Siegel R; Ehrlich R; Weinberger D; Rosenblatt I; Shani L; Yassur Y; Priel E; Kramer M Am J Ophthalmol; 2004 Oct; 138(4):602-7. PubMed ID: 15488787 [TBL] [Abstract][Full Text] [Related]
48. [Verteporfin and photosensitivity in diabetic]. Asensio Sánchez VM; Corral Azor A; García Pascual A Arch Soc Esp Oftalmol; 2003 May; 78(5):277-9. PubMed ID: 12789632 [TBL] [Abstract][Full Text] [Related]
49. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Lazić R; Gabrić N; Dekaris I; Gavrić M; Bosnar D Coll Antropol; 2007 Jan; 31 Suppl 1():71-5. PubMed ID: 17469756 [TBL] [Abstract][Full Text] [Related]
50. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Van de Moere A; Sandhu SS; Kak R; Mitchell KW; Talks SJ Ophthalmology; 2005 Nov; 112(11):1896-903. PubMed ID: 16214216 [TBL] [Abstract][Full Text] [Related]
51. Treatment of juxtafoveal choroidal neovascularization with photodynamic therapy using verteporfin in eyes with age-related macular degeneration. Hariprasad SM; Shah GK Ophthalmic Surg Lasers Imaging; 2005; 36(3):258-60. PubMed ID: 15957487 [TBL] [Abstract][Full Text] [Related]